Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Life Science Tools Market to Reach $258.6 Billion by 2030

Published

on

<!– Name:DistributionId Value:8749873 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1199811 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:4fa8abc4-56cb-4eab-83eb-b7183c6922ed –>

New York, Feb. 15, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Life Science Tools Industry” – https://www.reportlinker.com/p06032055/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Life Science Tools Market to Reach $258.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Life Science Tools estimated at US$133 Billion in the year 2022, is projected to reach a revised size of US$258.6 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2022-2030. Cell Biology, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$82.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Genomics segment is readjusted to a revised 8.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $48.4 Billion, While China is Forecast to Grow at 13% CAGR

The Life Science Tools market in the U.S. is estimated at US$48.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.1 Billion by the year 2030 trailing a CAGR of 13% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 8.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Select Competitors (Total 295 Featured)
– Abbott Laboratories Inc.
– Agilent Technologies, Inc.
– Becton, Dickinson and Company
– Bio-Rad Laboratories, Inc.
– Bruker Corporation
– Carl Zeiss AG
– Eppendorf SE
– F. Hoffmann-La Roche AG
– Hitachi High-Tech Corporation
– Illumina, Inc.
– Merck KGaA
– Oxford Instruments plc
– PerkinElmer Inc.
– QIAGEN N.V.
– Shimadzu Corporation
– Thermo Fisher Scientific Inc.

Read the full report: https://www.reportlinker.com/p06032055/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
A Prelude to Life Sciences Tools
Impact of Covid-19 and Global Economic Update
War & Inflation Supersede COVID-19 as Major Downside Risks for
the Global Economy in 2023 & Beyond
Here?s How Inflationary Pressures Affect the Economy
Russia-Ukraine War, the Primary Culprit Responsible for the
Hardships
Stubbornly High Inflation to Single Handedly Drag Down Global
Growth
Here?s What?s Causing the Current Spike in Inflation
EXHIBIT 1: War-Induced Commodity Price Increases & Broad Based
Price Pressures Mark the Return of Global Inflation in 2022 to
the Highest Level Seen Since 1996: Global Inflation Rates (In
%) for the Years 2019 Through 2024
EXHIBIT 2: War, Global Inflation, Cost of Living Crisis, Failed
Fiscal Policy Attempts to Restore Price Stability & Contain
Downside Risks to Result in Sharper-Than-Expected Slowdown in
Global Economic Growth: World Economic Growth Projections:
(Real GDP, Annual % Change) for the Years 2020, 2021, 2022
and 2023
EXHIBIT 3: Recession Triggered by Uncontrolled Inflation or
Unemployment, Which is the Greater Evil? Inflation Battling
Policy Measures to Slowdown Post Pandemic Recovery in
Unemployment Rates: Global Number of Unemployed People (In
Million) for Years 2019 Through 2023
EXHIBIT 4: Year Unemployed People (In Million) 2017, 2018,
2019, 2020, 2021, 2022 & 2023
Life Science Tools Market Gains Precedence during COVID-19
Pandemic
Competition
Players Pursue Product Launch & Innovation to Stay Relevant in
Competitive Life Science Tools Market
EXHIBIT 5: Life Science Tools – Global Key Competitors
Percentage Market Share in 2023 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
308 Players Worldwide in 2023 (E)
Global Market Analysis and Prospects
Global Life Science Tools Market Appears Primed for Healthy
Growth Ahead
Cell Biology Holds Significant Revenue Stake
Hospitals Remain Primary End-User Segment
North America Maintains Front Rank in Global Life Science Tools
Market
Asia-Pacific to Exhibit Impressive Growth
Salient Drivers Keeping Global Life Science Tools Market in
Good Shape
Technology Trends in the Life Sciences Domain
Connected Devices, IoT Ecosystems to Transform the Life Science
Landscape
Exponential Intelligence, Quantum Computing and Ambient
Technologies to Make Headway
Cloud Platforms Ease Data Sharing
Life Sciences to Gain with Blockchain Edge
AI-enabled Automation to Deliver Tangible Benefits for All
Cybersecurity Needs Grow for Life Sciences
Intertwined Factors with Major Implications for Life Science
Domain & Related Tools
Recent Market Activity
World Brands

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Trends in Life Science Sector Support Demand
Why Diagnostic Testing is Key to Mitigate Impact of Infectious
Diseases?
3D Cell Culture Transforms Life Sciences Industry
EXHIBIT 6: Global 3D Cell Culture Market in US$ Million: 2020 –
2027
Increasing Demand for 3D Cell Culture in Drug Discovery
Use of 3D Cell Culture for Regenerative Medicine
Proteomics Emerges as an Important Research Tool in Battle
against COVID-19
Proteomics Profiling to Expedite Drug Discovery
Proteomics at the Fore with Latest Advances
Mass Spectrometry (MS) Expands Application of Proteomics
AI and Machine Learning Address Shortcomings of Traditional
Equipment in Effectively Identifying Protein Patterns
mRNA Technology Gains Spotlight in Life Sciences
Innovations in Instrumentation Expand Functionality and Drive
Adoption of PCR
Synoptic Review of Quantitative PCR Technical Advancements in
the Recent Years
EXHIBIT 7: Global qPCR and dPCR Instrumentation Market in US$
Million: 2020-2025
Genome Sequencing Experiences Host of Evolutionary Waves
Greater Integration of Genomic Technologies in the Development
of Novel Diagnostics Tests
Next Generation Sequencing Drives the Market Growth
R&D Activity Remains Vibrant in NGS
The Need for Large-scale NGS Data Analysis Pushes for Cloud-
enabled Bioinformatics Services
Single-Cell Spatial Biology Technologies Poised to Emerge as an
Integral Aspect of Future Labs
Rising Application of Whole Genome Sequencing Drives Demand for
Faster Secondary Analysis Tools
Rapid Growth in Biopharma Industry and Rising Investments in R
&D to Boost Market Prospects
EXHIBIT 8: Global BioPharmaceuticals Market in US$ Billion:
2020 and 2026
Liquid Chromatography Drives Growth in New Application Markets
Innovative HPLC Products Inject New Growth
Digital Transformation of Life Sciences Sector Improves
Efficiency and Productivity
EXHIBIT 9: Key Initiators of Digital Transformation in Life
Sciences
Artificial Intelligence offers Multiple Opportunities
Wearable Devices Gains Popularity
The Cloud Technology Witnesses Rapid Growth
VR and E-pharmacy
Smart Quality
Growing R&D Spending in Pharma and Biotechnology Sectors
Presents Opportunities
EXHIBIT 10: Pharmaceutical R&D Spending Worldwide (USD Billion)
for 2015-2025
Technological Developments and Expanding End-Use Applications
to Bolster Growth in Mass Spectrometry
EXHIBIT 11: Global Chromatography Market (2022): Percentage
Share Breakdown of Value Sales by Chromatography Techniques
Miniature Mass Spectroscopy Instruments Get Popular
Increase in Healthcare Spending to Propel Demand for Life
Science Tools
EXHIBIT 12: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
The Rise of Data Analytics in Life Sciences
Data Science in Drug R&D
Data Sharing Emerges as a Significant Trend to Gain Competitive
Advantage

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Life Science Tools Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030

Table 2: World Recent Past, Current & Future Analysis for Life
Science Tools by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 3: World Historic Review for Life Science Tools by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 4: World 16-Year Perspective for Life Science Tools by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 5: World Recent Past, Current & Future Analysis for Cell
Biology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 6: World Historic Review for Cell Biology by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 7: World 16-Year Perspective for Cell Biology by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 8: World Recent Past, Current & Future Analysis for
Genomics by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 9: World Historic Review for Genomics by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 10: World 16-Year Perspective for Genomics by Geographic
Region – Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 11: World Recent Past, Current & Future Analysis for
Proteomics by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 12: World Historic Review for Proteomics by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 13: World 16-Year Perspective for Proteomics by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 14: World Recent Past, Current & Future Analysis for
Other Technologies by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 15: World Historic Review for Other Technologies by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 16: World 16-Year Perspective for Other Technologies by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 17: World Recent Past, Current & Future Analysis for
Healthcare by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 18: World Historic Review for Healthcare by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR

Table 19: World 16-Year Perspective for Healthcare by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 20: World Recent Past, Current & Future Analysis for
Biopharmaceutical Companies by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2022 through 2030 and % CAGR

Table 21: World Historic Review for Biopharmaceutical Companies
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 22: World 16-Year Perspective for Biopharmaceutical
Companies by Geographic Region – Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 23: World Recent Past, Current & Future Analysis for
Government & Academics by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Revenues in
US$ Million for Years 2022 through 2030 and % CAGR

Table 24: World Historic Review for Government & Academics by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 25: World 16-Year Perspective for Government & Academics
by Geographic Region – Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa for Years 2014, 2023 & 2030

Table 26: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR

Table 27: World Historic Review for Other End-Uses by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR

Table 28: World 16-Year Perspective for Other End-Uses by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES
Life Science Tools Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in the United States for 2023 (E)
Market Analytics
Table 29: USA Recent Past, Current & Future Analysis for Life
Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 30: USA Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 31: USA 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 32: USA Recent Past, Current & Future Analysis for Life
Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Life Science Tools by End-Use –
Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 34: USA 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Life Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 36: Canada Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 37: Canada 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 38: Canada Recent Past, Current & Future Analysis for
Life Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 40: Canada 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

JAPAN
Life Science Tools Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Japan for 2023 (E)
Market Analytics
Table 41: Japan Recent Past, Current & Future Analysis for Life
Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 42: Japan Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 43: Japan 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 44: Japan Recent Past, Current & Future Analysis for Life
Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 46: Japan 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

CHINA
Life Science Tools Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in China for 2023 (E)
Market Analytics
Table 47: China Recent Past, Current & Future Analysis for Life
Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 48: China Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 49: China 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 50: China Recent Past, Current & Future Analysis for Life
Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 51: China Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 52: China 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

EUROPE
Table 53: Europe Recent Past, Current & Future Analysis for
Life Science Tools by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2022 through 2030 and % CAGR

Table 54: Europe Historic Review for Life Science Tools by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR

Table 55: Europe 16-Year Perspective for Life Science Tools by
Geographic Region – Percentage Breakdown of Value Revenues for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 56: Europe Recent Past, Current & Future Analysis for
Life Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 57: Europe Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 58: Europe 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Life Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 61: Europe 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

FRANCE
Table 62: France Recent Past, Current & Future Analysis for
Life Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 63: France Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 64: France 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 65: France Recent Past, Current & Future Analysis for
Life Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 66: France Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 67: France 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

GERMANY
Table 68: Germany Recent Past, Current & Future Analysis for
Life Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 69: Germany Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 70: Germany 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 71: Germany Recent Past, Current & Future Analysis for
Life Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 72: Germany Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 73: Germany 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

ITALY
Table 74: Italy Recent Past, Current & Future Analysis for Life
Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 75: Italy Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 76: Italy 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 77: Italy Recent Past, Current & Future Analysis for Life
Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 78: Italy Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 79: Italy 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

UNITED KINGDOM
Table 80: UK Recent Past, Current & Future Analysis for Life
Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 81: UK Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 82: UK 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 83: UK Recent Past, Current & Future Analysis for Life
Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 84: UK Historic Review for Life Science Tools by End-Use –
Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 85: UK 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for Life
Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 87: Spain Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 88: Spain 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 89: Spain Recent Past, Current & Future Analysis for Life
Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 90: Spain Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 91: Spain 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Life Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 93: Russia Historic Review for Life Science Tools by
Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 94: Russia 16-Year Perspective for Life Science Tools by
Technology – Percentage Breakdown of Value Revenues for Cell
Biology, Genomics, Proteomics and Other Technologies for the
Years 2014, 2023 & 2030

Table 95: Russia Recent Past, Current & Future Analysis for
Life Science Tools by End-Use – Healthcare, Biopharmaceutical
Companies, Government & Academics and Other End-Uses –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 96: Russia Historic Review for Life Science Tools by
End-Use – Healthcare, Biopharmaceutical Companies, Government &
Academics and Other End-Uses Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2014 through 2021 and
% CAGR

Table 97: Russia 16-Year Perspective for Life Science Tools by
End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Life Science Tools by Technology – Cell Biology, Genomics,
Proteomics and Other Technologies – Independent Analysis of
Annual Revenues in US$ Million for the Years 2022 through 2030
and % CAGR

Table 99: Rest of Europe Historic Review for Life Science Tools
by Technology – Cell Biology, Genomics, Proteomics and Other
Technologies Markets – Independent Analysis of Annual Revenues
in US$ Million for Years 2014 through 2021 and % CAGR

Table 100: Rest of Europe 16-Year Perspective for Life Science
Tools by Technology – Percentage Breakdown of Value Revenues
for Cell Biology, Genomics, Proteomics and Other Technologies
for the Years 2014, 2023 & 2030

Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Life Science Tools by End-Use – Healthcare,
Biopharmaceutical Companies, Government & Academics and Other
End-Uses – Independent Analysis of Annual Revenues in US$
Million for the Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Life Science
Tools by End-Use – Healthcare, Biopharmaceutical Companies,
Government & Academics and Other End-Uses Markets – Independent
Analysis of Annual Revenues in US$ Million for Years 2014
through 2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for Life Science
Tools by End-Use – Percentage Breakdown of Value Revenues for
Healthcare, Biopharmaceutical Companies, Government & Academics
and Other End-Uses for the Years 2014, 2023 & 2030

ASIA-PACIFIC

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032055/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

JupiterOne and watchTowr announce partnership to protect business critical assets with broad exposure management capabilities

Published

on

jupiterone-and-watchtowr-announce-partnership-to-protect-business-critical-assets-with-broad-exposure-management-capabilities

SINGAPORE, May 2, 2024 /PRNewswire/ — watchTowr, a leader in external attack surface management (EASM) technology and fuelled by watchTowr Labs, a renowned vulnerability R&D capability, has formed a strategic partnership with JupiterOne. JupiterOne is a leader in cyber asset attack surface management (CAASM) technology. This collaboration enables customers to rapidly prioritize emerging threats within their constantly changing environments, focusing on fixing the most critical risks impacting their business, which enables an end-to-end continuous threat exposure management process (CTEM).

Over 28,000 CVE records were published in 2023; a figure that is expected to increase as attackers shorten the time from known vulnerability to exploit, reducing it from weeks to days. JupiterOne and watchTowr’s integrated solution empowers enterprises to discover their most critical and exploitable vulnerabilities, prioritize them with asset context based on business impact and receive an actionable remediation plan to improve security posture.
This partnership enables a complete continuous threat exposure management program, addressing the full spectrum of cyber risk management. The fully integrated solution provides continuous monitoring and assessment of both internal and external digital assets, allowing for prioritization and effective threat mitigation for a business’s most critical assets. “Our partnership with watchTowr is a game-changer” said Forte. “Combining our data aggregation with real-time asset discovery and automated security testing allows us to offer a unique, all-encompassing approach to exposure management.”
Benjamin Harris, CEO, watchTowr, said, “While the number of reported vulnerabilities continues to rise, the vulnerabilities that matter – in mission-critical, key systems – have exploded at an alarming rate. This reality, combined with the significant shift in speed by attackers to weaponize vulnerabilities – the ability to validate exploitability and prioritise actions based on real business risk has never been more vital. We’re excited to join forces with JupiterOne to give security teams around the globe this much-needed end-to-end capability.”
About JupiterOne:
JupiterOne is a cybersecurity startup delivering powerful software solutions to companies across all industries, providing deep insights to cyber assets and the relationships between, empowering security professionals to have true knowledge and ownership of their attack surfaces.
About watchTowr: 
watchTowr is a global cybersecurity technology company, built by former adversaries.
watchTowr’s world-class External Attack Surface Management and Continuous Automated Red Teaming technology is informed by years of experience compromising some of the world’s most targeted organisations and utilised by Fortune 500, financial services and critical infrastructure providers every day.
Photo – https://mma.prnewswire.com/media/2401497/watchTowr_JupiterOne.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jupiterone-and-watchtowr-announce-partnership-to-protect-business-critical-assets-with-broad-exposure-management-capabilities-302132392.html

Continue Reading

Artificial Intelligence

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Published

on

clarivate-declares-dividend-on-mandatory-convertible-preferred-shares

LONDON, May 1, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT; CLVT PR A) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the “Preferred Shares”), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.

On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price (“VWAP”) of Clarivate’s ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the “valuation period”). If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share. The mandatory conversion rate will be announced following the end of the valuation period. The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the “Statement of Rights” for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate’s annual report on Form 10-K for the fiscal year ended December 31, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clarivate-declares-dividend-on-mandatory-convertible-preferred-shares-302133633.html

Continue Reading

Artificial Intelligence

CGTN: 3rd CMG Forum in Beijing discusses AI development

Published

on

cgtn:-3rd-cmg-forum-in-beijing-discusses-ai-development

BEIJING, May 1, 2024 /PRNewswire/ — Focusing on the development of AI, the third CMG Forum was held on Monday in Beijing.

Li Shulei, a member of the Political Bureau of the Communist Party of China (CPC) Central Committee and the head of the Publicity Department of the CPC Central Committee, attended the opening of the event and delivered a speech.
Guests at the forum stressed the role of media in promoting the innovative application of AI as well as its governance.
Efforts should also be made to boost the development of AI in creating positive, healthy, diverse and high-quality content, so that AI can become a force for good and benefit mankind, they agreed.
They also called on media to accelerate intelligent transformation and help bridge international exchanges and cooperation on the governance of AI to facilitate its healthy, orderly and safe development.
Hosted by China Media Group (CMG), the forum attracted more than 200 participants from international organizations, media, think tanks and multinational companies.
“Innovation and breakthroughs in science and technology not only guide the development and progress of human civilization, but also bring uncertainty to the changing world,” said Shen Haixiong, vice minister of the Publicity Department of the CPC Central Committee and president of CMG. He called for efforts to jointly create valuable and responsible artificial intelligence.
AI technology is affecting every aspect of our lives. Thomas Bach, president of the International Olympic Committee (IOC), stated in a video speech that CMG has always been a partner of the IOC, bringing the charm of the Olympic Games to hundreds of millions of Chinese viewers. He said the IOC invites CMG to work together for the creation of a future with the application of AI in Olympic sports.
“From ancient inventions such as silk, printing and the compass to modern technological advances such as robotics, telecommunications and green technology, China has always been committed to innovation and creation,” said Daren Tang, director general of the World Intellectual Property Organization (WIPO). He said WIPO pays close attention to ensuring a balance between the opportunities and risks of artificial intelligence and is committed to strengthening cooperation to ensure that artificial intelligence is properly used.
https://news.cgtn.com/news/2024-04-30/3rd-CMG-Forum-in-Beijing-discusses-AI-development-1tdDcXvCexG/p.html

View original content:https://www.prnewswire.co.uk/news-releases/cgtn-3rd-cmg-forum-in-beijing-discusses-ai-development-302133410.html

Continue Reading

Trending